Ca silicide films-promising materials for silicon optoelectronics

Single-phase films of semiconductor and semimetallic calcium silicides (Ca2Si, CaSi, and CaSi2), as well as films with a significant contribution of Ca5Si3 and Ca14Si19 silicides, were grown on single-crystal silicon and sapphire substrates. The analysis of the crystal structure of the grown films was carried out and the criterion of their matching with silicon and sapphire substrates was determined. Some lattice-matching models were proposed, and the subsequent deformations of the silicide lattices were estimated. Film's optical functions, including the optical transparency, were calculated from the optical spectroscopy data and an extended comparison was performed with the results of ab initio calculations. The real limits of the optical transparency for the films on sapphire substrates were established. The maximum transparency limit (3.9 eV) was observed for the CaSi film. Based on an analysis of the photoelectric properties of Ca2Si/Si diodes on n- and p-type silicon substrates, a perspective of their applications in silicon optoelectronics was discussed

Integrable Structure of Conformal Field Theory, Quantum KdV Theory and Thermodynamic Bethe Ansatz

We construct the quantum versions of the monodromy matrices of KdV theory. The traces of these quantum monodromy matrices, which will be called as ``${\bf T}$-operators'', act in highest weight Virasoro modules. The ${\bf T}$-operators depend on the spectral parameter $\lambda$ and their expansion around $\lambda = \infty$ generates an infinite set of commuting Hamiltonians of the quantum KdV system. The ${\bf T}$-operators can be viewed as the continuous field theory versions of the commuting transfer-matrices of integrable lattice theory. In particular, we show that for the values $c=1-3{{(2n+1)^2}\over {2n+3}} , n=1,2,3,...$of the Virasoro central charge the eigenvalues of the ${\bf T}$-operators satisfy a closed system of functional equations sufficient for determining the spectrum. For the ground-state eigenvalue these functional equations are equivalent to those of massless Thermodynamic Bethe Ansatz for the minimal conformal field theory ${\cal M}_{2,2n+3}$; in general they provide a way to generalize the technique of Thermodynamic Bethe Ansatz to the excited states. We discuss a generalization of our approach to the cases of massive field theories obtained by perturbing these Conformal Field Theories with the operator $\Phi_{1,3}$. The relation of these ${\bf T}$-operators to the boundary states is also briefly described.Comment: 24 page

The Nature of Ferromagnetism in a System of Self-Ordered α-FeSi₂ Nanorods on a Si(111)-4° Vicinal Surface: Experiment and Theory

In this study, the appearance of magnetic moments and ferromagnetism in nanostructures of non-magnetic materials based on silicon and transition metals (such as iron) was considered experimentally and theoretically. An analysis of the related literature shows that for a monolayer iron coating on a vicinal silicon surface with (111) orientation after solid-phase annealing at 450–550 °C, self-ordered two-dimensional islands of α-FeSi2 displaying superparamagnetic properties are formed. We studied the transition to ferromagnetic properties in a system of α-FeSi2 nanorods (NRs) in the temperature range of 2–300 K with an increase in the iron coverage to 5.22 monolayers. The structure of the NRs was verified along with distortions in their lattice parameters due to heteroepitaxial growth. The formation of single-domain grains in α-FeSi2 NRs with a cross-section of 6.6 × 30 nm2 was confirmed by low-temperature and field studies and FORC (first-order magnetization reversal curves) diagrams. A mechanism for maintaining ferromagnetic properties is proposed. Ab initio calculations in freestanding α-FeSi2 nanowires revealed the formation of magnetic moments for some surface Fe atoms only at specific facets. The difference in the averaged magnetic moments between theory and experiments can confirm the presence of possible contributions from defects on the surface of the NRs and in the bulk of the α-FeSi2 NR crystal lattice. The formed α-FeSi2 NRs with ferromagnetic properties up to 300 K are crucial for spintronic device development within planar silicon technology

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk